Supplemental Figure 5 from Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer

Atish D. Choudhury,Lucia Kwak,Alexander Cheung,Kathryn M. Allaire,Jaqueline Marquez,David D. Yang, Abhishek Tripathi, Jacqueline M. Kilar, Meredith Flynn, Brianna Maynard, Rebecca Reichel, Amanda F. Pace, Brandon K. Chen,Eliezer M. Van Allen,Kerry Kilbridge,Xiao X. Wei,Bradley A. McGregor,Mark M. Pomerantz,Rupal S. Bhatt, Christopher J. Sweeney,Glenn J. Bubley,Heather A. Jacene,Mary-Ellen Taplin,Franklin W. Huang,Lauren C. Harshman,Lawrence Fong

crossref（2024）

Cited 0|Views8

No score

Abstract

Kaplan-Meier estimates of time to treatment failure (TTF), radiographic progression-free survival (rPFS), and overall survival (OS) by A. baseline CD4+FoxP3- (effector) proportion above (high) vs. below (low) median. B. baseline CD8+ proportion above vs. below median. C. baseline CD8+ / CD4+FoxP3+ (Treg) ratio above vs. below median. N.B. Patients were event-free for 2 months as they need to have on treatment biopsy at week 8 of treatment.

Translated text

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined